NovoCure (NVCR) Cash from Financing Activities (2016 - 2026)
NovoCure's Cash from Financing Activities history spans 13 years, with the latest figure at -$166000.0 for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 103.16% to -$166000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$456.8 million, a 579.04% decrease, with the full-year FY2025 number at -$451.3 million, down 599.74% from a year prior.
- Cash from Financing Activities hit -$166000.0 in Q1 2026 for NovoCure, up from -$559.5 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for NVCR hit a ceiling of $100.5 million in Q3 2025 and a floor of -$559.5 million in Q4 2025.
- Historically, Cash from Financing Activities has averaged -$19.4 million across 5 years, with a median of $3.1 million in 2022.
- The widest YoY moves for Cash from Financing Activities: up 100417.0% in 2025, down 20937.77% in 2025.
- Tracing NVCR's Cash from Financing Activities over 5 years: stood at $3.4 million in 2022, then tumbled by 43.99% to $1.9 million in 2023, then skyrocketed by 40.58% to $2.7 million in 2024, then tumbled by 20937.77% to -$559.5 million in 2025, then skyrocketed by 99.97% to -$166000.0 in 2026.
- Business Quant data shows Cash from Financing Activities for NVCR at -$166000.0 in Q1 2026, -$559.5 million in Q4 2025, and $100.5 million in Q3 2025.